GlobeNewsWire
17 Jun 2026, 10:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri trial failed to meet its primary endpoint of demonstrating a statistically significant reduction in Stage III-IV cancers. — Failure of a primary endpoint in a major clinical trial directly undermines the core value proposition of the company's lead product.
-0.80A securities fraud class action lawsuit has been filed against GRAIL and its executives alleging they misled investors regarding the NHS-Galleri trial design and results. — Legal action for securities fraud creates significant contingent liabilities and damages management credibility.
-0.50GRAIL's stock price dropped approximately 50.55% following the disclosure of the trial's failure. — While this is a historical price action, it confirms the market's severe negative repricing of the company's fundamentals.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities fraud class action lawsuit following a 50% stock price drop and failure to meet a primary trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
